

Optimal regimens regimens based on PK/PD cutoff evaluation of ceftiofur against *Actinobacillus pleuropneumoniae* in swine

Da Sun

Huazhong Agriculture University <https://orcid.org/0000-0001-6181-4807>

Kun Mi

Huazhong Agriculture University

Haihong Hao

Huazhong Agriculture University

Shuyu Xie

Huazhong Agriculture University

Dongmei Chen

Huazhong Agriculture University

Lingli Huang (✉ huanglingli@mail.hzau.edu.cn)

National Reference Laboratory of Veterinary Drug Residues and MAO Key Laboratory for Detection of Veterinary Drug Residues, Huazhong Agricultural University

Research article

Keywords: Ceftiofur, *Actinobacillus pleuropneumoniae*, epidemiologic cutoff value, pharmacokinetic/pharmacodynamics cutoff, dosage

Posted Date: July 27th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-22198/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Veterinary Research on September 29th, 2020. See the published version at <https://doi.org/10.1186/s12917-020-02589-9>.

Abstract

Background *Actinobacillus pleuropneumoniae*, formerly known as *Haemophilus pleuropneumoniae*, can cause pleuropneumoniae in pigs of different ages, leading to significant mortality. Ceftiofur was the first cephalosporin antibiotic used in animals that was effective against gram-negative and gram-positive bacteria. This study aimed to determine epidemiologic cutoff value (ECV), and pharmacodynamic-pharmacokinetic cutoff. Establishing Clinical breakpoint of ceftiofur against *Actinobacillus pleuropneumoniae* based on the pharmacodynamic-pharmacokinetic cutoff.

Results The epidemiologic cutoff value was 0.125 µg/mL. The results of the pharmacodynamic study showed that the MICs of BW39 were 0.5 µg/mL and 1 µg/mL under in vitro and ex-vivo conditions, respectively, and the minimal bactericidal concentrations (MBCs) under in vitro and ex vivo conditions were both 1 µg/mL. The time-killing profiles of ceftiofur against BW39 were time-dependent with a partly concentration-dependent pattern. According to the inhibitory sigmoid E max model, the AUC 24 h /MIC values for the bacteriostatic, bactericidal, and elimination effects in serum were 45.73, 63.83, and 69.04 h for healthy pigs, respectively. Based on the Monte Carlo simulation, the CO PD was calculated as 2 µg/mL, and the optimized dosage regimen of ceftiofur against *Actinobacillus pleuropneumoniae* to achieve bacteriostatic, bactericidal, and elimination effects over 24 h was 2.13, 2.97, and 3.42 mg/kg for the 50% target attainment rate (TAR) and 2.47, 3.21, and 3.70 mg/kg for the 90% TAR, respectively.

Conclusions In conclusion, we reveal the EOFF and PK/PD cutoff values of ceftiofur against *A. pleuropneumoniae* in piglets. However, with the paucity of clinical data for ceftiofur to establish a clinical cutoff against *A. pleuropneumoniae*, the PK/PD cutoff value of 2 µg/mL will be recommended as surrogate. According to the PK/PD data and the MIC distribution in China, the single bactericidal dose was 3.21 mg/kg for the 90% target, which would be more able to cure *Actinobacillus pleuropneumoniae* and avoid the emergence of resistance for clinical ceftiofur use of ceftiofur in piglet.

Background

Porcine pleuropneumonia caused by *Actinobacillus pleuropneumoniae* is a highly contagious respiratory disease that causes hemorrhage, purulent and fibrous pleuropneumonia. The disease is widely distributed and causes severe losses to the pig industry. The morbidity of the disease can be as high as 100%, but usually varies from 30 to 50%, with a case fatality rate as high as 50% [1]. There are currently 18 serotypes of *Actinobacillus pleuropneumoniae* [2, 3], and the prevalent serotypes vary in different countries and regions worldwide.

Ceftiofur was the first third-generation cephalosporin antibiotic used in animals. It is effective for gram-negative bacteria and gram-positive bacteria and has a good clinical therapeutic effect against animal respiratory diseases [4]. In 1988, the United States Food and Drug Administration (FDA) first approved ceftiofur sodium for use in bovine respiratory bacterial diseases. The FDA has approved cefiofur

hydrochloride, ceftiofur sodium and ceftiofur crystal-free acid for the treatment of respiratory diseases of pigs, cattle, horses, goats and sheep[5-7].

Clinical breakpoint are MIC values, which are used in clinical microbiology laboratories to categorize microorganisms as clinically[8]. Establishing clinical breakpoint contains three parts: (i) an epidemiological cut-off value (ECOFF), described by EUCAST as the ECOFF, it defines the upper end(>95%) of the wild type MIC distribution. (ii) a MIC to define a PK/PD cut-off, named by EUCAST as the PK/PD breakpoint. It is calculated from selected PK/PD index in target population(iii) clinical cut-off described by EUCAST in human medicine, it is related to clinical outcomes(cure vs non-cure) and requires specific investigations during prospective clinical trials[9]. Although the CLSI has established the breakpoint of ceftiofur against *Actinobacillus pleuropneumoniae*, considering that the use of antibiotics and drug resistance in China is totally different, it is necessary to formulate the relevant criteria for ceftiofur against *Actinobacillus pleuropneumoniae* in China based on the local situation.

The abuse of antibiotics and unreasonable doses of antimicrobial agents are the main factors that contribute to the development of resistance[10, 11]. Existing data have suggested that the resistance rate of *Actinobacillus pleuropneumoniae* to tetracyclines and penicillin reached 90% and showed different degrees of resistance to macrolides and aminoglycosides. However, *Actinobacillus pleuropneumoniae* is still highly sensitive to ceftiofur [12-14] and Clinical breakpoint should be define for each animal species and for the relevant bacterial target pathogens. Therefore, we need to use scientific methods to determine the reasonable dosage of ceftiofur and establish drug resistance criteria to protect the clinical efficacy of ceftiofur. Previous study [15]has shown the PK data of ceftiofur sodium and ceftiofur hydrochloride and the recommended dosage of ceftiofur for the treatment of swine respiratory disease in the U.S. and in Europe ranged from 3 to 5 mg of ceftiofur equivalents (CE)/kg body weight. PK/PD integration modeling data can provide an optimal drug dosage strategy, reducing resistance development, which is a key method to evaluate the clinically relevant relationship between time, drug concentration, and effect. However, there are no data supporting the recommended dosage of ceftiofur based on the PD of ceftiofur against *Actinobacillus pleuropneumoniae* in China.

The purposes of this investigation were to (i) study the pharmacokinetic/pharmacodynamic of ceftiofur against *Actinobacillus pleuropneumoniae*, (ii) formulate a rational dosage strategy and review the preceding recommended dosage based on PK/PD modeling for ceftiofur against *Actinobacillus pleuropneumoniae*, and (iii) establish a clinical breakpoint based on pharmacokinetic/pharmacodynamic cutoff values.

Results

MIC distribution and epidemiologic cutoff value

The MIC distribution of ceftiofur against *Actinobacillus pleuropneumoniae* is shown in Figure 1. The MIC values ranged from 0.0075 to 4 µg/mL. The MIC₅₀ and MIC₉₀ were calculated to be 0.015 and 0.5 µg/mL,

respectively. we selected the serotype 1 strain *App BW39* whose MIC was similar to MIC₉₀(0.5 µg/mL) to analyzed for PD study in broth and serum. The ECV using the freeware statistic software “ECOFFinder” was 0.125 µg/mL, encompassing 99.9% of the wild-type isolates.

MICs, MBCs, MPC and PAE

The MIC values of ceftiofur against *App BW39* were 0.5 µg/mL and 1 µg/mL *in vitro* and *ex vivo*, respectively, and the MBC values were both 2 µg/mL *in vitro* and *ex vivo*. The MBC/MIC ratios were 2 and 1 *in vitro* and *ex vivo*, respectively, indicating that ceftiofur is a bactericidal drug. The MPC value of ceftiofur against *App BW39* was 1.6 µg/mL, and the MSW was 1-1.6 µg/mL. The post antibiotic effect (PAE) values after exposure to the concentrations of 1MIC, 2MIC and 4MIC were 0.33, 0.41 and 0.66h for 1h exposure and 0.73, 0.92 and 1.17 h for 2 h exposure, respectively (Table 1). The result suggested PAE had a positive correlation with exposure time. PAE was also prolonged with the increase of drug concentration, but the degree of enhancement was weak.

Time-killing curves

The time-killing curves of ceftiofur against *BW39 in vitro* and *ex vivo* are shown in Figures 2 and 3. When the drug concentration was 1/2 MIC-1 MIC, bacterial growth was not inhibited. Concentrations between 1 MIC and 2 MIC showed a slight inhibitory effect on the bacterial growth. Ceftiofur achieved a maximum bactericidal effect from 4 MIC-8 MIC. The *ex vivo* killing curve showed that the plasma collected between 0.33 and 2 h achieved the maximum bactericidal effect at the highest ceftiofur concentration. When the concentration was below the MIC at 96 h, ceftiofur no longer inhibited the growth of bacteria.

Pharmacokinetic analysis of ceftiofur in plasma

LOD and LOQ of HPLC methods for detecting DFC were 0.03 µg/mL and 0.08 µg/mL, respectively. The linear range of the standard and working curve of DFC ranged from 0.1 to 50 µg/mL, with a coefficient of determination (R^2) of 0.9999 and 0.9987, respectively. The recovery of ceftiofur in plasma ranged from 82.95% to 84.38%. The pharmacokinetic parameters calculated using non-compartment model analysis after I.M. (5 mg/kg BW) administration in healthy pigs are shown in Table 2. DFC concentrations were measured at different times shown in Figure 4.

PK/PD integration and analysis

The PK/PD indices were determined by integrating the *in vivo* PK data and **the *ex vivo* time-killing curve**. The ratios of C_{max}/MIC, AUC_{24 h}/MIC, and T > MIC were 22.33±1.98, 358.84±57.42 h, and 72.2±7.32 h, respectively. The values of the PK/PD index versus antibacterial effects in serum were simulated by the sigmoid E_{max} model. The model parameters of Hill coefficient, N, E_{max} and AUC 24 h/MIC of the different levels are presented in Table 3. The values of the AUC_{24 h}/MIC ratio required for bacteriostatic activity (E = 0), bactericidal activity (E = -3), and bacterial elimination (E = -4) were 45.73, 63.83, and 69.04 h, respectively.”

Dose estimation

According to the PK-PD integration model, the PK-PD index, AUC 24 h/MIC, was altered based on different outcomes in healthy swine. The prediction of ceftiofur curing *A. pleuropneumoniae* diseases for the 50% and 90% targets was calculated by the Monte Carlo simulation and dosage equation, which are shown in Figure 5. The doses predicted to exhibit bacteriostatic, bactericidal, and elimination effects for *A. pleuropneumoniae* over 24 h were 2.13, 2.97, and 3.42 mg/kg for the 50% target attainment rate (TAR) and 2.47, 3.21, and 3.70 mg/kg for the 90% TAR, respectively, based on Crystal Ball software.

CO_{PD} determination with Monte Carlo Simulation

According to the MIC distribution, AUC_{24 h} derived from healthy pigs and the PK-PD target (AUC_{24 h}/MIC)_{ex} of 63.83 h, 10,000 subjects were simulated by Monte Carlo simulation. The PTA (possibility target achievement) values were calculated as 88.94%, 100% and 100% when the MICs (PK-PD cut-off) were defined as 4, 2 and 1 µg/ml, respectively (Table 4). Therefore, the CO_{PD} for ceftiofur against *Actinobacillus pleuropneumoniae* was defined as 2 µg/mL, for the current dose of 5mg/kg by IM route.

Discussion

Ceftiofur, whether administered as hydrochloride or sodium salt, was metabolized rapidly to desfuroylceftiofur. The plasma half-life of ceftiofur sodium after intravenous dosing in swine was approximately 10 min [16]. The previous study[17] has tested the susceptibility of ceftiofur and its metabolite desfuroylceftiofur against *Actinobacillus pleuropneumoniae*(n=50), the MIC₉₀ of ceftiofur is 0.0078 µg/mL and 0.015 µg/mL for desfuroylceftiofur, which suggests ceftiofur can be predictive of in vitro activity of ceftiofur and its major metabolite, desfuroylceftiofur. In our study, we determined the vitro susceptibility of ceftiofur, instead of desfuroylceftiofur, against 135 *Actinobacillus pleuropneumoniae* strains. The MIC values ranged from 0.0075µg/mL to 4 µg/mL, and the MIC₅₀ and MIC₉₀ values were 0.015 µg/mL and 0.5 µg/mL, respectively, which were slightly different from the results of ceftiofur against 50 *Actinobacillus pleuropneumoniae* strains (MIC ranged from 0.0039-0.0015 µg/mL) [17].

The epidemiologic cutoff was established based on the pretest of drug susceptibility and then analyzed by statistical methods. At present, CLSI and EUCAST guidelines mainly involve analysis by nonlinear regression, which was proposed by Turnidge [18]. EUCAST based on the nonlinear regression complied the ECOFFinder software[19] the principle of which is the same as Turnidge's method. In this study, the epidemiologic cutoff was 0.125 µg/L according to the ECOFFinder results.

There are currently 18 serotypes of *Actinobacillus pleuropneumoniae* [2, 3]. The prevalent serotypes are different all over the world. The main prevalent serotypes in Canada are serotypes 1, 3 and 5, those in Europe are serotypes 1, 2, 5, 7 and 9 [20], and those in the United States are serotypes 1, 5 and 7 [21]. However, serotypes 1, 3, 5 and 7 were the main prevalent serotypes in China[22]. Moreover, serotype 1 was more virulent than other serotypes[23, 24] Therefore, A strain App BW39, Whose MIC was similar to

MIC₉₀(0.5 µg/mL) and serotype was serotype 1, was analyzed for PD study in broth and serum . According to the MIC and MBC values *in vitro* and *ex vivo*, the MBC/MIC ratio was 2 and 1, respectively. Therefore, ceftiofur is a bactericidal drug with an MBC/MIC ratio < 4 [25]. The results of *in vitro* and *ex vivo* killing curves suggested, when the drug concentration was 1/2 MIC-1 MIC, bacterial growth was not inhibited. the concentration from 4 MIC-8 MIC achieved the maximum bactericidal effect. with the concentration increasing, the bactericidal effect increased and achieved the maximum bactericidal effect at 4MIC-8MIC. These findings suggest that ceftiofur has a time-dependent inhibition activity same with a partly concentration-dependent pattern against *Actinobacillus pleuropneumoniae* both *in vitro* and *ex vivo*[26].

To establish a pharmacokinetic/pharmacodynamics cutoff, we needed to obtain the PK-PD parameters, MIC distribution and pharmacodynamic targets. The most appropriate PK/PD index to determine the antibacterial efficacy and predict the therapeutic efficacy for β-lactam antibiotics is the percentage of duration that the concentration of free drug is greater than the MIC (%T > MIC) [27]. The killing curve shows that ceftiofur has a time-dependent inhibition activity same with a partly concentration-dependent pattern against *Actinobacillus pleuropneumoniae*. Moreover, PK/PD index depends on the shape of the plasma exposure curve which may differ widely between the many modalities of Antimicrobial drug administration, such as antimicrobial drug was incorporated in food or drinking water or administered by oral. VetCAST explore alternatives, in particular the possible use of AUC/MIC as a default index. The index of the AUC/MIC ratio was also used to describe the character of the antibacterial activity of time-dependent killing with prolonged persistent efficacy [28]. In our manuscript, The PK/PD index (AUC/MIC), using an inhibitory sigmoidal E_{max} model, showed a favorable correlation (r² = 0.9967) with the predicted antibacterial efficacy. For these reasons, the AUC/MIC parameter was regarded as the most appropriate PK/PD index to describe the antibacterial activity of ceftiofur in serum. An AUC/MIC ratio > 125 h is generally considered the best activity indicator [29, 30]. However, the target parameters might be different for different drugs, target organisms or bacteria[31]. For example, the AUC_{24 h}/MIC values for three levels of preventive, therapeutic, and bacterial eradication were 28.40, 29.51 and 29.13 h, respectively, in previous study on PK/PD modeling of Ceftiofur Sodium against *Haemophilus parasuis* infection in pigs[26]. In another study, the AUC_{24 h}/MIC values for three levels of preventive, therapeutic, and bacterial eradication were 24.6, 43.8 and 58.4 h, respectively [32]. Prior to our study, no PK-PD integration modeling analyses were performed for ceftiofur against *Actinobacillus pleuropneumoniae*. In our study, the inhibitory sigmoidal E_{max} model was employed for the simulation of the PK/PD integration model to obtain the AUC_{24 h}/MIC value. The *ex vivo* values of AUC_{24 h}/MIC of ceftiofur against bacteriostatic, bactericidal and eradication were 45.73, 63.83 and 69.04 h, respectively. Through Monte Carlo simulations, when the MIC values were 2 µg/mL and 4 µg/mL, the probability of target attainment was 100% and 88.94%, respectively. Therefore, the CO_{PD} was calculated as 2 µg/mL, for the current dose of 5 mg/kg by IM route.

The PK of healthy pigs corresponded to a non-compartmental model. The peak concentration reached 22.33±3.17 at 0.66-2h, the elimination half-time was 19.51±2.76 h, and AUC was 358.84±91.87µg·h/mL,

which was similar to previous study[3]. The PK of ceftiofur may differ from that of diseased pigs. Previous study has demonstrated that infected pigs may have higher values of Vz/F and CL/F, but lower values of AUC,

MRT and t1/2z compared with non-infected pigs.

PD-PD integration modeling can be used to select rational dose regimes in veterinary medicine[30]. Based on the dose estimation equation and Monte Carlo simulation, the 'fu' in the equation was the free fraction of the drug in plasma. Ceftiofur had a high protein binding rate, which was 90% in cow and adult cattle [33, 34], The EMA[35] reported that the protein binding of ceftiofur and its metabolite DFC in swine was 0.7, which was applied in this research. According to the MIC distribution in China, the predicted daily doses for the 50% and 90% targets of ceftiofur with bactericidal activity against *Actinobacillus pleuropneumoniae* were 2.97 and 3.21 mg/kg body weight, respectively. The Monte Carlo simulation combined with the dosage equation and taking into consideration the PK/PD integration could set the target percentage to simulate models for all data in relation to incidence in swine [36, 37].

CBP is used to define susceptibility and resistance. In general, the determination of CBP should take into account the ECOFF, COPD and clinical cutoff values [24, 25]. Under the clinically recommended dose(5mg/kg), the ceftiofur CO_{PD} value (2 µg/mL) against *A. pleuropneumoniae* was higher than the ECOFF value (0.125 µg/mL). It probably means that the current dose (5.0 mg/ kg) could guarantee clinical efficacy to treat the wild-type populations of *A. pleuropneumoniae*. In fact, our calculated accurate dose of ceftiofur hydrochloride for a PTA≥90% was 3.21mg/kg. Previous study[3] has shown the similarity of the pharmacokinetic parameters of the sodium and hydrochloride formulations of ceftiofur, similar therapeutic efficacy therefore can be inferred for the two products. So, Considering the MIC distribution in China, the dose of ceftiofur could be 3.21mg/kg, However, owing to the paucity of relevant data to bridge the relationship between MIC and clinical cure, it is practically difficult to determine a clinical cutoff in veterinary medicine [24, 26]. In our study, CO_{PD} values contains the ECOFF values, and the CO_{PD}(2 µg/mL) will therefore be recommended as surrogate. Although the ECOFF or PK/PD cutoff could not replace the CBP, it still provides a useful interpretative criterion.

Conclusions

In conclusion, we reveal the EOFF and PK/PD cutoff values of ceftiofur against *A. pleuropneumoniae* in piglets. However, with the paucity of clinical data for ceftiofur to establish a clinical cutoff against *A. pleuropneumoniae*, the PK/PD cutoff value of 2 µg/mL will be recommended as surrogate. Moreover, according to the PK/PD data and the MIC distribution in China, the single bactericidal dose was 3.21 mg/kg for the 90% target, which would be more able to cure *Actinobacillus pleuropneumoniae* and avoid the emergence of resistance for clinical ceftiofur use of ceftiofur in piglet.

Methods

Chemicals and reagents

The standard ceftiofur hydrochloride (det. purity: 97.9%) purchased from Dr. Ehrenstorfer (Augsburg, Germany) and 5% ceftiofur hydrochloride injection purchased from Pfizer Animal Health Co., Ltd., Canada, were used during the study. All the chemical reagents used were HPLC grade.

Bacterial strain isolation

E. coli ATCC 25922 was purchased from American Type Cell Culture and used as a quality control strain for drug susceptibility testing. *Actinobacillus pleuropneumoniae* serotype 1 (BW39) was used to determine the EOFF and CO_{PD} values. A total of 101 *Actinobacillus pleuropneumoniae* strains were donated by the International Research Center for Animal Diseases, China State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University. Thirty-four *Actinobacillus pleuropneumoniae* strains were isolated from the tissue of infected pigs. The strains were stored at -80°C prior to each experiment. Prior to testing, each isolate was subcultured at least three times in TSA and TSB containing 5% newborn calf serum and 1% NAD (Zhejiang Tianhang Biotechnology Co., Ltd.).

Determination of antimicrobial susceptibility and epidemiologic cutoff

The susceptibility of 135 *Actinobacillus pleuropneumoniae* strains to ceftiofur was determined by inoculating the strains on TSA agar plates supplemented with newborn calf serum and 1% NAD and incubating the plates at 37 °C in an atmosphere containing 5% CO₂ for 24 h; the susceptibility was measured using the standard agar dilution method with concentrations of ceftiofur between 0.00375-32 µg/ml, according to CLSI[38] protocols. The MIC distribution was constructed and converted into a cumulative log-normal distribution. Then, nonlinear regression was employed to fit the cumulative log₂-transformed MIC data to obtain a range of optimum wild-type MIC distributions, which contained the wild-type MIC in the range of 0.1% and 99.9%, and to calculate the probability of MIC data falling within the cutoff range. The optimum fit was defined as the fit where the difference between the estimate of the isolate number and the actual number was minimal. The cutoff value would encompass at least 95% of the wild-type isolates [39]. A wild-type cutoff (CO_{WT}) was developed based on the MIC distribution following CLSI M37-A3. The CO_{WT} value was calculated by ECOFFinder software (J. Turnidge, Kahlmeter, and Kronvall 2006), which is available on the CLSI website (<https://clsi.org/education/microbiology/ecoffinder/>).

Pharmacodynamics of ceftiofur against *BW39*

MIC, MBC and MPC determination

The minimum inhibitory concentration (MIC) of ceftiofur against BW39 (serotype 1) was determined by the broth micro dilution method according to the CLSI (Clinical and Laboratory Standards Institute, 2015) and in serum, as *vitro* MIC and *ex vivo* MIC. The MIC was determined as the lowest ceftiofur concentration that visibly inhibited the growth of bacteria at the end of the 24 h incubation period. For the MBC of ceftiofur against BW39, 100 μ L from each well was subjected to 10-fold or more dilution with broth and serum, as *vitro* MBC and *ex vivo* MBC; 10 μ L of each solution was spread on TSA agar plates and incubated at 37 °C for 24 h for colony forming unit (CFU) counting. The MBC was defined as the lowest drug concentration that resulted in a 99.9% reduction in the bacterial density. The mean was expressed as the final result.

The mutant prevention concentration (MPC) was determined by the agar method according to the procedures of Blondeau [40]. Exponential growth phase bacteria were pelleted by centrifuging at 3000 rpm at 4 °C. The pellet was then diluted to 3×10^{10} CFU/mL with TSB medium. An aliquot of 100 μ L of the 10^{10} CFU/mL bacterial suspension was cultured on TSA agar plates containing various concentrations of ceftiofur (0×MIC, 1×MIC, 2×MIC, 4×MIC, 8×MIC, 16×MIC, 32×MIC, and 64×MIC) obtained from a series of two-fold dilutions. Inoculated plates were incubated for 72 h, and colonies were counted every 24 h. All MPC determinations were performed in duplicate. The MPC was defined as the lowest ceftiofur concentration with no visible bacterial growth on agar plates after incubation for 72 h.

Bacterial growth and time-killing curve of *BW39 in vitro* and *ex vivo*

The BW39 isolate was selected to determine the growth curve and time-killing curve in TSB broth and serum. The *in vitro* and *ex vivo* growth curves of the BW39 isolate were established by plotting time versus \log_{10} CFU/mL. An aliquot of 5 mL of BW39 grown to mid-log phase with a starting inoculum of 10^6 CFU/mL was added to 5 mL of TSB broth supplemented with serial concentrations of ceftiofur corresponding to 0×MIC, 1×MIC, 2×MIC, 4×MIC, 8×MIC, 16×MIC, and 32×MIC for the *in vitro* time-killing curve. In addition, an aliquot of 5 mL of BW39 grown to the mid-log phase with a starting inoculum of 10^6 CFU/mL was co-incubated with 5 mL sterilized blank serum added with ceftiofur corresponding to the

concentration of ceftiofur in serum, which was collected from healthy pigs at different time points (0, 0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72 and 96 h) after I.M. administration of a single injection of 5 mg/kg ceftiofur hydrochloride for the determination of the *ex vivo* time-killing curve. The tubes were incubated at 37 °C with 5% CO₂. Each culture was serially diluted 10-fold with sterile saline, and 100 µL of each dilution was spread onto TSA agar plates at different time points (0, 2, 4, 6, 8, 12, and 24 h). Then, the bacterial count (CFU/mL) was determined after incubation for 24 h at 37 °C with 5% CO₂. The limit of detection was 10 CFU/mL. The *in vitro* and *ex vivo* time-killing curves of ceftiofur against BW39 were established by plotting the time versus log₁₀ CFU/mL. The experiment was tested in triplicate.

In vitro PAE determination

Approximately 1.8 mL exponential phase *A.pleuropneumoniae* BW39 (1.0×10^7 CFU/mL) was mixed with 0.2 mL ceftiofur, to generate final concentrations of 1 MIC, 2 MIC and 4 MIC. A 0.2 mL aliquot of physiological saline was used as control. Volumes were cultured in glass tubes and grown for 1h and 2 h to induce PAE production. 100 µL cultured medium was mixed with 0.9 mL TSB medium and cultured 24 h at 37 °C with 5% CO₂. 100 µL samples were taken at 0, 1, 2, 4, 6, 8, and 12 h, and serially diluted 10-fold with sterile physiological saline to count cells. Each treatment was performed four times. Growth curve for *A.pleuropneumoniae* BW39, at different ceftiofur concentrations were established, and T (time required for bacterial numbers to be 10 times higher than 0 h in the test groups) and C (time required for the bacterial numbers to be 10 times higher than 0 h in control groups) values were calculated. PAE was calculated as the difference between T and C (PAE = T - C).

Pharmacokinetics of ceftiofur in plasma of pigs

Animals

Six 6-week-old healthy castrated crossbred piglets (Duroc×Landrace×Yorkshire) pigs with an average weight of 15±2 kg were purchased from the Livestock and Poultry Breeding Center of Hubei Province (Wuhan, China). The animals were acclimatized for a period of one week before the experiment. The temperature and relative humidity of the housing environment were kept at 18–25 °C and 45–65%, respectively. The piglets were maintained in accordance with the National Standards for Laboratory Animals of China (GB 14925–2010), and allowed ad libitum access to water and antibiotic-free food. The

ethanasia procedure was carried out by pentobarbital sodium with intravenous injection when study was finished. All animal experiment procedures were approved by the Institutional Animal Care and Use Committee at Huazhong Agricultural University (HZAUSW-2016-007).

Samples collection

Six pigs were received ceftiofur hydrochloride injection at a dose of 5 mg/kg·b.w by intramuscular injection of neck. Blood samples (5 mL) from each pig of each group were gently collected from the jugular vein at 0, 0.33, 0.66, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 72 and 96 h. Plasma samples were obtained by centrifuging the blood at 3500 rpm/min for 10 min, and the samples were stored at -20 °C prior to the analysis and analysis within 3 days after sampling.

Sample analysis

DFC concentration were measured by HPLC described by previous study[26] to represent ceftiofur plasma concentration, as ceftiofur is rapidly metabolized to DFC in piglets.

Extraction: 0.5 mL plasma was mixed with 7 mL of 0.4% DTE-borate buffer. The mixture was incubated for 15 min at 50 °C in a water bath, with a 10 s vortexing every 3 min. Samples were then centrifuged after cooling to 25 °C, and the supernatant was collected.

Solid phase extraction: An Agilent HLB column (60 mg/3 cc) was activated and equilibrated consecutively with 3 mL methanol and ultrapure water. Extracted materials were added to the HLB column and a flow rate set at 1 mL/min. The column was then eluted with 5 mL methanol, after which the eluate was concentrated by nitrogenblow at 35°C. The concentrated solution was vortexed with 0.5 mL ultrapure water, sonicated for 5 min. The DFC standard was added to 0.5 mL plasma (to achieve final concentrations of 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10.0, 20.0 and 50 µg/mL) and prepared with same process as samples from test groups.

The quantitative analysis of ceftiofur in plasma was performed with a Water 2695 series HPLC with a UV detector at a wavelength of 266 nm. A ZORBAX Stable Bond-C18 column (250 mm× 4.6 mm, i.d. 5 µm, Agilent) was used to achieve chromatographic separation. The mobile phase consisted of 0.1%

trifluoroacetic acid (phase A) and acetonitrile (phase B) at a flow rate of 1 mL/min at 30 °C with isometric elution conditions (86:14, v/v).

The concentration-time data for ceftiofur in plasma samples harvested from healthy pigs were analyzed by WinNonlin 5.2.1 software (Pharsight Corporation, Mountain View, CA, USA) to obtain the pharmacokinetic parameters.

Pharmacokinetic/pharmacodynamic integration and dose estimations

There are three standard indices ($f\%T > MIC$, fC_{max}/MIC , and $fAUC_{0-24h}/MIC$) for an antibiotic [41]. The inhibitory sigmoid Emax model (Hill equation) was analyzed the integration of AUC24h/MIC ratio in vitro and bacteria count change (CFU/ml) in serum during 24 hr incubation. The model equation was described as follows:

$$E = E_{max} - \frac{(E_{max} - E_0) \cdot C^N}{C^N + EC_{50}^N}$$

where E is the antibacterial effect measured as the change in the bacterial count (\log_{10} CFU/mL) in plasma sample after 24 h of incubation compared with the initial incubation, E_0 is the change in \log_{10} difference in bacterial count in the control sample after 24 h of incubation; E_{max} is the maximum antibacterial effect determined as the difference in \log_{10} CFU/mL in the sample after the incubation, EC_{50} is the PK/PD parameter value producing 50% of the maximum antibacterial effect; C is the PK/PD parameter value in the effect compartment (the *ex vivo* site, that is plasma); and N is the Hill coefficient, which describes the steepness of the PK/PD parameter-effect curve.

PK/PD parameter values corresponding to the E value (derived from the sigmoid E_{max} equation) in plasma were used to deduce an optimal dose regimen. The potential optimal dosage was calculated using the following equation:

$$\text{Dose} = \frac{(AUC_{24h} / MIC)_{ex} \times MIC}{fu} \times CL / F$$

where *MIC* is the *ex vivo* minimum inhibitory concentration; $(AUC_{24\text{ h}}/MIC)_{ex}$ is the target end point for optimal efficacy; *CL* is the clearance; *fu* is the free fraction of ceftiofur in plasma; and *F* is the bioavailability of ceftiofur.

The distribution probabilities for predicted daily dosage were performed to achieve simulated 50% and 90% TAR under 1,000 trials with Crystal Ball software (*version 11.1.2*, Oracle, United States).

Monte Carlo simulation and the pharmacokinetic/pharmacodynamics cutoff (CO_{PD})

A Monte Carlo simulation (MCS) with 10,000 iterations was conducted using Crystal Ball software (*version 7.2.2*) (Oracle, United States) based on PK parameters and calculated PK/PD targets $(AUC_{24\text{ h}}/MIC)$ when each possible MIC and the target $AUC_{24\text{ h}}/MIC$ achieving a bactericidal action ($E = -3$). The $AUC_{24\text{ h}}$ was assumed to be normally. CO_{PD} was defined as the maximal MIC value at which the corresponding PTA was $\geq 90\%$ [42].

Abbreviations

APP: *Actinobacillus pleuropneumoniae*,

AST: Antimicrobial susceptibility testing

AUC/MIC: The area under the concentration-time curve to MIC ratio

CLSI: Clinical & Laboratory Standards Institute

CO_{PD}: PK/PD (pharmacokinetic/pharmacodynamic) cutoff value (named by EUCAST as the PK/PD breakpoint)

DFC: Desfuroylceftiofur;

EMA: European Medicines Agency

ECOFF: Epidemiological cutoff value [synonym of wild-type cutoff value (COWT)]

EUCAST: European Committee on AST

HPLC: High performance liquid

LOD: Limited of Detection

LOQ: Limited of Quantitation

MBC: Minimal bactericidal concentration

MIC: Minimal inhibitory concentration

NAD: Nicotinamide Adenine Dinucleotide

PAE: Post-antibiotic effect

PK/PD: Pharmacokinetic/pharmacodynamic

PTA: Probability of target attainment

TSA: Tryptic Soy Agar

TSB: Tryptic Soy Broth

Declarations

Ethics approval and consent to participate

All animal studies were carried out in accordance with the National Standards for Laboratory Animals of China (GB 14925–2010). The protocol of in vivo experiment and strain isolation procedures from animals were approved by the Institutional Animal Care and Use Committee at Huazhong Agricultural University (HZAUSW-2016-007).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed in this study are available from the corresponding author on reasonable request.

Competing interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

Funding

The authors thank the financial supporting from National key research and development program in China (2016YFD0501310;2018YFD0500301). The funding body had no role in the design of the study, collection, analysis, and interpretation of data and in writing the manuscript.

Author contributions

LLH, DS, DMC conceived this work. DS, HH, SYX designed the experiment. DS and MK performed the experiments. DS wrote the manuscript. LLH and DS improved the language. All authors reviewed the manuscript.

Acknowledgments

Not applicable.

References

1. Hoflack G, Maes D, Mateusen B, Verdonck M, De KA: **Efficacy of tilmicosin phosphate (Pulmotil premix) in feed for the treatment of a clinical outbreak of *Actinobacillus pleuropneumoniae* infection in growing-finishing pigs.** *J Vet Med B Infect Dis Vet Public Health* 2010, **48**(9):655-664.
2. Sarkozi R, Makrai L, Fodor L: **Identification of a Proposed New Serovar of *Actinobacillus Pleuropneumoniae*: Serovar 16.** *Acta Vet Hung* 2015, **63**(4):444-450.
3. Bosse JT, Li Y, Sarkozi R, Fodor L, Lacouture S, Gottschalk M, Casas Amoribieta M, Angen O, Nedbalcova K, Holden MTG *et al*: **Proposal of serovars 17 and 18 of *Actinobacillus pleuropneumoniae* based on serological and genotypic analysis.** *Vet Microbiol* 2018, **217**:1-6.
4. Brown SA, Hanson BJ, Mignot A, ., Millérioux L, ., Hamlow PJ, Hubbard VL, Callahan JK, Kausche FM: **Comparison of plasma pharmacokinetics and bioavailability of ceftiofur sodium and ceftiofur hydrochloride in pigs after a single intramuscular injection.** *Journal of Veterinary Pharmacology & Therapeutics* 2010, **22**(1):35-40.
5. Beconibarker MG, Davidson KL, Hornish RE, Arnold TS, Craigmill AL, Gilbertson TJ, Smith EB, Vidmar TJ, Hoffman GA, Gatchell CL: **[C-14] Ceftiofur Sodium-Absorption, Distribution, Metabolism, and Excretion in Sheep Following Intramuscular Injections.** *J Agr Food Chem* 1995, **43**(6):1589-1597.
6. Beconi-Barker MG, Roof RD, Millerioux L, Kausche FM, Vidmar TH, Smith EB, Callahan JK, Hubbard VL, Smith GA, Gilbertson TJ: **Determination of ceftiofur and its desfuroylceftiofur-related metabolites in swine tissues by high-performance liquid chromatography.** *J Chromatogr B Biomed Appl* 1995, **673**(2):231-244.
7. Jaglan PS, Yein FS, Hornish RE, Cox BL, Arnold TS, Roof RD, Gilbertson TJ: **Depletion of intramuscularly injected ceftiofur from the milk of dairy cattle.** *J Dairy Sci* 1992, **75**(7):1870-1876.
8. Mouton JW: **Setting Clinical MIC Breakpoints from a PK/ PD Point of View: It Is the Dose That Matters.** *Fundamentals of Antimicrobial Pharmacokinetics and Pharmacodynamics* 2013:45-64.
9. Toutain PL, Bousquet-Melou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P: **En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.** *Front Microbiol* 2017, **8**:2344.
10. Burgess DS: **Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance.** *Chest* 1999, **115**(3):19s-23s.

11. Wang JY, Hao HH, Huang LL, Liu ZL, Chen DM, Yuan ZH: **Pharmacokinetic and Pharmacodynamic Integration and Modeling of Enrofloxacin in Swine for Escherichia coli.** *Front Microbiol* 2016, **7**.
12. Archambault M, Harel J, Goure J, Tremblay YDN, Jacques M: **Antimicrobial Susceptibilities and Resistance Genes of Canadian Isolates of Actinobacillus pleuropneumoniae.** *Microb Drug Resist* 2012, **18**(2):198-206.
13. Kim B, Min K, Choi C, Cho WS, Cheon DS, Kwon D, Kim J, Chae C: **Antimicrobial susceptibility of Actinobacillus pleuropneumoniae isolated from pigs in Korea using new standardized procedures.** *J Vet Med Sci* 2001, **63**(3):341-342.
14. Vanni M, Merenda M, Barigazzi G, Garbarino C, Luppi A, Tognetti R, Intorre L: **Antimicrobial resistance of Actinobacillus pleuropneumoniae isolated from swine.** *Vet Microbiol* 2012, **156**(1-2):172-177.
15. Brown SA, Hanson BJ, Mignot A, Millerioux L, Hamlow PJ, Hubbard VL, Callahan JK, Kausche FM: **Comparison of plasma pharmacokinetics and bioavailability of ceftiofur sodium and ceftiofur hydrochloride in pigs after a single intramuscular injection.** *J Vet Pharmacol Ther* 1999, **22**(1):35-40.
16. BeconiBarker MG, Smith EB, Arnold TS, Hornish RE, Vidmar TJ, Gatchell CL: **Metabolism of [C-14]ceftiofur hydrochloride in swine after intramuscular injections.** *J Agr Food Chem* 1997, **45**(7):2606-2611.
17. Salmon SA, Watts JL, Yancey RJ, Jr.: **In vitro activity of ceftiofur and its primary metabolite, desfuoylceftiofur, against organisms of veterinary importance.** *J Vet Diagn Invest* 1996, **8**(3):332-336.
18. Turnidge J, Kahlmeter G, Kronvall G: **Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values.** *Clin Microbiol Infec* 2006, **12**(5):418-425.
19. Ismail NA, Omar SV, Joseph L, Govender N, Blows L, Ismail F, Koornhof H, Dreyer AW, Kaniga K, Ndjeka N: **Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study.** *Ebiomedicine* 2018, **28**(C):136-142.
20. Hennessy KJ, Iandolo JJ, Fenwick BW: **Serotype Identification of Actinobacillus-Pleuropneumoniae by Arbitrarily Primed Polymerase Chain-Reaction.** *J Clin Microbiol* 1993, **31**(5):1155-1159.
21. Mulks MH, Buysse JM: **A Targeted Mutagenesis System for Actinobacillus-Pleuropneumoniae.** *Gene* 1995, **165**(1):61-66.
22. Zhu X, Li Y: **Review of Prevalence and Serotype Distribution for ActinobacillusPleuropneumoniae(in chinese).** *Progressin Veterinary Medicine* 2017, **10**:111-113.
23. Brandreth SR, Smith IM: **Comparative Virulence of Some English Strains of Haemophilus-Pleuropneumoniae Serotype-2 and Serotype-3 in the Pig.** *Res Vet Sci* 1987, **42**(2):187-193.
24. Rogers RJ, Eaves LE, Blackall PJ, Truman KF: **The comparative pathogenicity of four serovars of Actinobacillus (Haemophilus) pleuropneumoniae.** *Aust Vet J* 1990, **67**(1):9-12.
25. Tato M, Lopez Y, Morosini MI, Moreno-Bofarull A, Garcia-Alonso F, Gargallo-Viola D, Vila J, Canton R: **Characterization of variables that may influence ozenoxacin in susceptibility testing, including MIC and MBC values.** *Diagn Micr Infec Dis* 2014, **78**(3):263-267.

26. Li XD, Chi SQ, Wu LY, Liu C, Sun T, Hong J, Chen X, Chen XG, Wang GS, Yu DJ: **PK/PD modeling of Ceftiofur Sodium against Haemophilus parasuis infection in pigs.** *BMC Vet Res* 2019, **15**(1):272.
27. Toutain PL, Bousquet-Melou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P: **En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.** *Front Microbiol* 2017, **8**.
28. Andes D, Craig WA: **Animal model pharmacokinetics and pharmacodynamics: a critical review.** *International Journal of Antimicrobial Agents* 2002, **19**(4):261-268.
29. Meinen JB, McClure JT, Rosin E: **Pharmacokinetics of Enrofloxacin in Clinically Normal Dogs and Mice and Drug Pharmacodynamics in Neutropenic Mice with Escherichia-Coli and Staphylococcal Infections.** *Am J Vet Res* 1995, **56**(9):1219-1224.
30. Toutain PL, Del Castillo JRE, Bousquet-Melou A: **The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.** *Res Vet Sci* 2002, **73**(2):105-114.
31. Ahmad I, Hao H, Huang L, Sanders P, Wang X, Chen D, Tao Y, Xie S, Xiuhua K, Li J *et al*: **Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle.** *Front Microbiol* 2015, **6**:588.
32. Dorey L, Pelligand L, Cheng ZR, Lees P: **Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.** *Plos One* 2017, **12**(5).
33. Meyer S, Giguere S, Rodriguez R, Zielinski RJ, Grover GS, Brown SA: **Pharmacokinetics of intravenous ceftiofur sodium and concentration in body fluids of foals.** *J Vet Pharmacol Ther* 2009, **32**(4):309-316.
34. Wang J, Peng H, Kong J, Zhao T, Zhang S, Cao X: **Pharmacokinetic profile of Ceftiofur Hydrochloride Injection in lactating Holstein dairy cows.** *J Vet Pharmacol Ther* 2018, **41**(2):301-306.
35. **SUMMARY OF PRODUCT CHARACTERISTICS** [https://www.ema.europa.eu/en/documents/product-information/naxcel-epar-product-information_en.pdf]
36. Dorey L, Pelligand L, Cheng Z, Lees P: **Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.** *Plos One* 2017, **12**(5):e0177568.
37. Lei Z, Liu Q, Yang B, Ahmed S, Xiong J, Song T, Chen P, Cao J, He Q: **Evaluation of Bioequivalence of Two Long-Acting 20% Oxytetracycline Formulations in Pigs.** *Front Vet Sci* 2017, **4**:61.
38. CLSI: **Performance standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals.** 2018, Wayne, PA: Clinical and Laboratory Standards Institute.
39. Turnidge J, Kahlmeter G, Kronvall G: **Statistical Characterisation of Bacterial Wild-Type MIC Value Distributions and the Determination of Epidemiological Cut-off Values.** *Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2006, **12**(5):418–425.
40. Blondeau JM, Shebelski SD, Hesje CK: **Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory**

concentrations and mutant prevention concentrations. *International Journal of Antimicrobial Agents* 2015, **45**(6):594-599.

41. Nielsen EI, Friberg LE: **Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.** *Pharmacological Reviews* 2013, **65**(3):1053-1090.

42. Turnidge J, Paterson D: **Setting and revising antibacterial susceptibility breakpoints.** *Clinical Microbiology Reviews* 2007, **20**(3):391-408.

Tables

Table 1 Post antibiotic effect (PAE) after 1h and 2h

Ceftiofur	1h	2h
($\mu\text{g}/\text{mL}$)	(h)	(h)
MIC	0.33	0.73
2MIC	0.41	0.92
4MIC	0.66	1.17

Table 2 Pharmacokinetic parameters of Ceftiofur after I.M administration (5 mg/kg) in healthy pigs

Parameters	Units	Healthy
$\text{AUC}_{0-24\text{h}}$	$\mu\text{g}\cdot\text{h}/\text{mL}$	358.84 ± 91.87
$\text{AUC}_{0-\infty}$	$\mu\text{g}\cdot\text{h}/\text{mL}$	372.05 ± 97.35
C_{max}	$\mu\text{g}/\text{mL}$	22.33 ± 3.17
T_{max}	hr	0.66-2
$T_{1/2}$	h	19.51 ± 2.76
Ke	h^{-1}	0.04 ± 0.01
CL/F	$\text{mL}/\text{kg}/\text{h}$	282.49 ± 52.91
MRT_{0-t}	h	22.82 ± 1.83
$\text{MRT}_{0-\infty}$	h	26.33 ± 2.94

Table 3 PK/PD analysis of data acquired from ex vivo time-killing curve of ceftiofur against a representative strain of *APP* BW39 in serums

Parameter	Unit	healthy
E_{\max}	Log ₁₀ CFU/ml	3.68
E_0	Log ₁₀ CFU/ml	-6.88
$E_{\max}-E_0$	Log ₁₀ CFU/ml	10.56
EC ₅₀	h	21.97
N	-	1.78
AUC 24h /MIC for bacteriostatic	h	45.73
AUC 24h /MIC for bactericidal	h	63.83
AUC 24h /MIC for elimination	h	69.04

Table 4 The AUC₂₄/MIC values calculated with Monte Carlo simulation for PTA

Dose (mg/kg)	AUC ($\mu\text{g}\cdot\text{h}/\text{mL}$)	MIC($\mu\text{g}/\text{mL}$)		
		1	2	4
5	358.84±91.87	100%	100%	88.94%

Figures




Figure 1

Distribution of MIC for ceftiofur against 135 strains *Actinobacillus pleuropneumoniae*




Figure 2

In vitro time-killing curves of ceftiofur against *Actinobacillus pleuropneumoniae*




Figure 3

Ex vivo time-killing curves of ceftiofur against *Actinobacillus pleuropneumoniae*




Figure 4

The concentration curve of ceftiofur in plasma by 5 mg/kg intramuscular injection (n=6)




Figure 5

The predicted doses of ceftiofur curing *A. pleuropneumoniae* for 50% and 90% TAR. A1:50% TAR of bacteriostatic effect; A2:90% TAR of bacteriostatic effect; B1:50% TAR of bactericidal effect; B2: 90% TAR of bactericidal effect; C1:50% TAR of elimination effect; C2: 90% TAR of elimination effect

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [ARRIVEguidelines.docx](#)
- [supplementary.docx](#)